UrologyNews.net

Urology Xagena

Search results for "metastatic bladder cancer"

Results from a phase I open-label study that showed the investigational cancer immunotherapy MPDL3280A ( anti-PDL1 ) shrank tumours ( overall response rate ) in 43% ( 13/30 ) of people previously trea ...


In the IMvigor 210 study, the investigational cancer immunotherapy Atezolizumab ( MPDL3280A; anti-PD-L1 ) shrank tumors ( objective response rate; ORR; the primary end point of this study ) in people ...


Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO ( European Society for Medical Oncology ) Congres ...